Pherecydes Pharma organizes a scientific symposium throughout the twenty third Nationwide Infectious Science Days

Phage therapy in 2022: the French experience

PARIS – (BUSINESS WIRE) – Regulatory reports:

Pherecydes Pharma (FR0011651694 – ALPHE, authorized by PEA-PME), a biotechnology company specializing in precision phage therapy for the treatment of resistant and / or complicated bacterial infections, today announces that it will participate in a scientific symposium “Phage therapy: the French experience”, which will take place on 15 June 2022 from 17:15 to 18:30 in the amphitheater A Palais des Congrès de Bordeaux, in the 23rdth National Infectious Days (JNI).

The symposium was moderated by Dr. F.-A. Dauchy from CHU in Bordeaux will host the following interventions:

  • Phagotherapy and IOA. Compassionate cases and clinical studies, including PhagoDAIR: Ex. T. Ferry (Lyon)

  • Phagotherapy and diabetic ulcer infections of the feet. The state of knowledge. PhagoPied: Prof. A. Sotto (Nîmes)

  • Phagotherapy and lung infections. Preclinical results. Planned clinical trials: Dr. A. Bleibtreu (Paris)

Pascal Birman, Medical Director of Pherecydes Pharma, comments: “Antibiotic resistance is a major public health issue and is a central theme during this 23th JNI edition. This symposium is an opportunity to highlight the interest in phage therapy through several clinical studies that will take place in the various indications and compassionate treatments that have already been conducted with our phages. Pherecydes Pharma and its partners make every effort to ensure that these studies provide useful answers to improve the treatment of patients with antibiotic-resistant infections. »

About Pherecydes Pharma

Pherecydes Pharma, founded in 2006, is a biotechnology company that develops treatments for resistant bacterial infections that are responsible for many serious infections. The company has developed an innovative approach, precise phage therapy, based on the use of phages, natural viruses that kill bacteria. Pherecydes Pharma develops a portfolio of phages targeting the 3 most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli a Pseudomonas aeruginosa. The concept of accurate phage therapy has been successfully applied to dozens of patients in compassionate treatment under the supervision of the National Medicines Agency (ANSM). Headquartered in Nantes, Pherecydes Pharma relies on a team of approximately twenty experts from the pharmaceutical, biotechnology and academic research industries.

For more information, www.pherecydes-pharma.com

WARNING

This release contains non-functional materials, including, but not limited to, certain statements regarding future results and other future events. These statements are based on the current view and assumptions of the Company’s management. They include known and unknown risks and uncertainties that could cause actual results, profitability and expected events to differ materially. In addition, Pherecydes Pharma, its shareholders and its affiliates, directors, officers, advisors and employees have not verified the accuracy of any statistical information or information contained in this document, nor do they provide any guarantees. derived from third party sources or industry publications. These statistics and prospective information are used in this press release for information purposes only.

contacts

Pherecydes Pharma
Thibaut du Fayet

Operations Director

[email protected]

NewCap
Dušan Orešanský / Olivier Bricaud

Investor relations

[email protected]
T: 01 44 71 94 92

NewCap
Arthur Rusty

Media relations

[email protected]
T. : 01 44 71 94 98

Leave a Comment